<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218293</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AF-CRF-2016-013</org_study_id>
    <nct_id>NCT03218293</nct_id>
  </id_info>
  <brief_title>Thrombolysis and RIPC in Acute Ischemic Stroke</brief_title>
  <acronym>tripcais</acronym>
  <official_title>The Recovery of Nerve Function Deficient of Combined Intravenous Thrombolysis and Remote Ischemic Post-conditioning in Acute Ischemic Stroke.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Remote ischemic postconditioning (RIPC) is suggested to protect the cerebral cell against&#xD;
      ischemia in various settings. However, the effect of RIPC in patients with acute ischemic&#xD;
      stroke who undergo thrombolysis has yet to be examined. In this single-center, randomized&#xD;
      controlled trial, we examined the effect of RIPC on the resolution of nerve function&#xD;
      deficient in response to thrombolysis. Patients in the RIPC group had five cycles of 5-min&#xD;
      cuff inflation followed by 3-min deflation to the bilateral upper arm after thrombolysis. The&#xD;
      primary endpoint was the recovery of nerve function deficient assessed by National Institutes&#xD;
      of Health Stroke Scale(NIHSS), Activities of Daily Living(ADL), Modified Rankin Scale(mRS),&#xD;
      CT cerebral perfusion imaging (CTP) and CT angiography(CTA). Secondary endpoints included the&#xD;
      following: angiogenesis assessed by the level of vascular endothelial growth factor (VEGF),&#xD;
      basic fibroblast growth factor (bFGF).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">October 31, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the percentage of patients with a favorable outcome, defined as a score of 0 or 1 on the modified Rankin scale (mRS).</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the percentage of functional recovery at discharge and at day 90, as measured by the NIHSS, the Barthel index (BI) and the mRS</measure>
    <time_frame>Day 90 and at discharge(up to day 14)</time_frame>
    <description>we measured how many patients achieved a score of 0 or 1 for the NIHSS, 95 for the BI, and 0 - 2 for the mRS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma biomarker concentrations</measure>
    <time_frame>Day 1 and at discharge ( up to day 14)</time_frame>
    <description>Venous blood was drawn before the administration of IV tPA and at the end of hospitalization to determine the effect of repeated RIPC on anti-inflammatory (S100-β), vascular (VEGF, bFGF), anti-edema (MMP9), anti-oxidants (OH1) and other pathways (BDNF, HSP).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>mortality rate</measure>
    <time_frame>up to 3 months.</time_frame>
    <description>three-month mortality rate</description>
  </other_outcome>
  <other_outcome>
    <measure>the rate of symptomatic hemorrhagic transformation</measure>
    <time_frame>up to 36 hours</time_frame>
    <description>Defined by European Cooperative Acute Stroke Study III classification</description>
  </other_outcome>
  <other_outcome>
    <measure>Early neurological deterioration</measure>
    <time_frame>up to 24 hours after IV tPA</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The tolerance index</measure>
    <time_frame>up to 14 days</time_frame>
    <description>the proportion of patients that could complete every RIPC treatment session during his/her hospital stay.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Acute Ischemic Stroke, Cerebral Embolism and Thrombosis</condition>
  <arm_group>
    <arm_group_label>RIPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remote ischemic postconditioning（RIPC）：Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after thrombolysis while in-hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blank control group(BC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Blank control group:Patients in the BC group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin, 100-300 mg/d) and lipid-lowering (atorvastatin, 20 mg/d) drugs,throughout the 14 days in-hospital period without remote ischemic postconditioning after thrombolysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RIPC device (IPC-906X)</intervention_name>
    <description>Patients in the RIPC group had five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm after thrombolysis.</description>
    <arm_group_label>RIPC</arm_group_label>
    <other_name>Thrombolysis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  In accordance with the Guideline of Thrombolysis in Acute Ischemic Stroke and&#xD;
             accomplish intravenous thrombolytic therapy using alteplase;&#xD;
&#xD;
          -  The consciousness of patients are conscious,somnolence,confusion and stupor，can comply&#xD;
             better with the RIPC treatment;&#xD;
&#xD;
          -  Acute ischemic stroke confirmed by cranial CT/MRI;&#xD;
&#xD;
          -  Provision of written informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of cerebral embolism,cerebral hemorrhage, brain tumor, brain trauma or other&#xD;
             brain lesion;&#xD;
&#xD;
          -  Severe cardiac, liver, or kidney disease, malignancy, systemic organ dysfunction;&#xD;
&#xD;
          -  Blood pressure &lt;90/60 mmHg or &gt;200/110 mmHg after treatment;&#xD;
&#xD;
          -  Dementia or mental illness;&#xD;
&#xD;
          -  History of major surgery or trauma 4 weeks prior to admission;&#xD;
&#xD;
          -  Failure to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guogang Luo, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 6, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Intracranial Embolism</mesh_term>
    <mesh_term>Intracranial Embolism and Thrombosis</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Embolism and Thrombosis</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

